東陽光藥(01558.HK)授權九州通磷酸奧司他韋中國內地獨家總代理權
格隆匯11月1日丨東陽光藥(01558.HK)公佈,於2019年11月1日,公司與九州通醫藥集團股份有限公司九州通(600998.SH)訂立了一份戰略合作框架協議,據此,公司將其產品磷酸奧司他韋(可威)三個單獨規格及其他藥品(受限於協議雙方的進一步協商),授權九州通在中國大陸地區OTC渠道獨家總代理權。合作期限為三年。
九州通是一家於上海證券交易所上市的公司,其主要從事醫藥流通業務。截至本公告日,以各公司董事所知所信,並經過所有合理查詢,九州通及其最終實益擁有人,均為公司及公司關聯人士以外的獨立第三者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.